GLPwatch
Papers (9189)
Page 39 of 154, ranked by citation count.
- A 2021 Update on the Use of Liraglutide in the Modern Treatment of 'Diabesity': A Narrative Review.
- Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study.
- Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.
- Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study.
- Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line.
- Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis.
- Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction.
- Long-Term Activation of Glucagon-like peptide-1 receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes.
- Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis.
- Semaglutide in Adults with Type 1 Diabetes and Obesity.
- Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
- Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
- The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by D-amphetamine and augments lithium effects in mice: Relevance for bipolar disorder.
- Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study.
- A red light-controlled probiotic bio-system for in-situ gut-brain axis regulation.
- Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models.
- Intranasal Delivery of Exendin-4 Confers Neuroprotective Effect Against Cerebral Ischemia in Mice.
- Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity.
- Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations.
- Clinical effectiveness of semaglutide on weight loss, body composition, and muscle strength in Chinese adults.
- Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus.
- GLP-1R activation attenuates the progression of pulmonary fibrosis via disrupting NLRP3 inflammasome/PFKFB3-driven glycolysis interaction and histone lactylation.
- Liraglutide reduces lipid accumulation in steatotic L‑02 cells by enhancing autophagy.
- Human Sperm Express the Receptor for Glucagon-like Peptide-1 (GLP-1), Which Affects Sperm Function and Metabolism.
- Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers.
- A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats.
- Characterization of attributes and in vitro performance of exenatide-loaded PLGA long-acting release microspheres.
- Liraglutide treatment causes upregulation of adiponectin and downregulation of resistin in Chinese type 2 diabetes.
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.
- Functional activity of murine intestinal mucosal cells is regulated by the glucagon-like peptide-1 receptor.
- Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo.
- Changes in whole metabolites after exenatide treatment in overweight/obese polycystic ovary syndrome patients.
- Differential effects of GLP-1 receptor agonist on foam cell formation in monocytes between non-obese and obese subjects.
- Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
- The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
- Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling.
- Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.
- Safety and tolerability of medications approved for chronic weight management.
- Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis.
- The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide.
- Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management.
- Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland.
- Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes.
- Semaglutide inhibits ischemia/reperfusion-induced cardiomyocyte apoptosis through activating PKG/PKCε/ERK1/2 pathway.
- Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial.
- Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.
- Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection.
- Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice.
- Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial.
- Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.
- Anti-obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline.
- Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials.
- The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis.
- Semaglutide ameliorates obesity-induced cardiac inflammation and oxidative stress mediated via reduction of neutrophil Cxcl2, S100a8, and S100a9 expression.
- Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
- Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
- Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis.
- Liraglutide restores impaired associative learning in individuals with obesity.
- Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study.
- Interspecies modeling and prediction of human exenatide pharmacokinetics.